Compare JLL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JLL | INSM |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | 48000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 22.4B |
| IPO Year | 1997 | 2000 |
| Metric | JLL | INSM |
|---|---|---|
| Price | $324.03 | $117.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 24 |
| Target Price | ★ $365.33 | $201.17 |
| AVG Volume (30 Days) | 286.3K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 7.91 | N/A |
| Revenue | ★ $26,115,600,000.00 | N/A |
| Revenue This Year | $7.71 | $182.31 |
| Revenue Next Year | $6.99 | $65.19 |
| P/E Ratio | $41.01 | ★ N/A |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $259.83 | $90.39 |
| 52 Week High | $393.84 | $212.75 |
| Indicator | JLL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 44.20 |
| Support Level | $313.17 | $97.66 |
| Resistance Level | $337.10 | $119.54 |
| Average True Range (ATR) | 9.17 | 5.39 |
| MACD | -2.85 | -1.02 |
| Stochastic Oscillator | 5.77 | 13.84 |
Jones Lang LaSalle is a global commercial real estate services and investment management company that helps clients buy, build, occupy, manage, and invest in property across office, industrial, retail, multifamily, hotel, and data center assets. For over 200 years, clients have trusted JLL, a Fortune 500 company, tracing its roots to firms including LaSalle Partners (founded in Chicago in 1968) and the centuries-old London firm Jones Lang Wootton, which merged in 1999 to form the modern JLL. Today the firm is a leading global commercial real estate services and investment management company with operations in over 80 countries, and a global workforce of more than 113,000, as of early 2026.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.